Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
publish chart | backtests Type: candle | line | advanced    Timeframe: intraday | daily | weekly | monthly  Settings
CPHD [NASD]
Cepheid
Technology | Scientific & Technical Instruments | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.22 Insider Own0.82% Shs Outstand67.11M Perf Week-1.15%
Market Cap2.60B Forward P/E161.71 EPS next Y0.24 Insider Trans-27.62% Shs Float66.43M Perf Month2.97%
Income-14.20M PEG- EPS next Q-0.04 Inst Own- Short Float12.57% Perf Quarter9.08%
Sales345.86M P/S7.53 EPS this Y-873.76% Inst Trans2.54% Short Ratio20.51 Perf Half Y27.12%
Book/sh3.92 P/B9.90 EPS next Y- ROA-4.28% Target Price40.91 Perf Year6.53%
Cash/sh1.52 P/C25.54 EPS next 5Y18.33% ROE-5.76% 52W Range28.12 - 46.00 Perf YTD14.62%
Dividend- P/FCF- EPS past 5Y0.00% ROI-5.57% 52W High-15.63% Beta1.18
Dividend %- Quick Ratio1.94 Sales past 5Y20.67% Gross Margin53.55% 52W Low38.02% ATR0.96
Employees945 Current Ratio2.90 Sales Q/Q18.95% Oper. Margin-3.86% RSI (14)52.96 Volatility2.34% 2.19%
OptionableYes Debt/Eq0.01 EPS Q/Q105.31% Profit Margin-4.11% Rel Volume0.70 Prev Close38.55
ShortableYes LT Debt/Eq0.01 EarningsApr 18 AMC Payout- Avg Volume407.03K Price38.81
Recom2.00 SMA200.63% SMA501.81% SMA2008.82% Volume286,819 Change0.67%
19-Apr-13Reiterated UBS Buy $40 → $42
19-Apr-13Reiterated Mizuho Buy $37 → $42
25-Jan-13Reiterated UBS Buy $43 → $40
16-Nov-12Initiated Mizuho Buy $37
19-Oct-12Reiterated ISI Group Sell $30.50 → $29
27-Sep-12Reiterated ISI Group Sell $35 → $32.50
30-Aug-12Initiated Cantor Fitzgerald Hold $40
14-May-12Downgrade GARP Research Buy → Neutral
06-Jan-12Upgrade RBC Capital Mkts Sector Perform → Outperform $38 → $42
11-Oct-11Reiterated RBC Capital Mkts Sector Perform $30 → $38
22-Jul-11Reiterated Oppenheimer Outperform $33 → $38
14-Jul-11Reiterated Canaccord Genuity Buy $36 → $40
17-Mar-11Initiated Oppenheimer Outperform $33
28-Jan-11Reiterated Wedbush Neutral $23 → $25
28-Jan-11Reiterated RBC Capital Mkts Sector Perform $20 → $22
14-Dec-10Downgrade Wedbush Outperform → Neutral $22 → $23
09-Dec-10Reiterated UBS Neutral $22 → $26
16-Nov-10Initiated Canaccord Genuity Buy $27
21-May-10Initiated GARP Research Buy
23-Apr-10Upgrade Robert W. Baird Neutral → Outperform $16 → $24
15-May-13 12:00AM  Primecap Rides Health to Top Growth Fund: Riskless Return at Bloomberg
13-May-13 02:20PM  Neutral Rating Restated for Cepheid Zacks
10-May-13 01:04PM  CEPHEID Financials EDGAR Online Financials
07-May-13 04:05PM  Cepheid Welcomes Executive Vice President of Global Operations PR Newswire
09:16AM  CEPHEID Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Principal Officers, Fi EDGAR Online
02-May-13 01:40PM  DexCom Loss Narrower than Est. Zacks
10:31AM  CEPHEID Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
09:08AM  CEPHEID Files SEC form 10-Q, Quarterly Report EDGAR Online
01-May-13 04:05PM  Cepheid to Webcast Upcoming Financial Presentations PR Newswire
29-Apr-13 01:40PM  ResMed's Earnings Beat; Revs Lag Zacks
26-Apr-13 12:50PM  FDA Taking More Aggressive Approach in Areas of Totally Unmet Medical Need, Granting Breakthrough Status to New Drugs in Development if No Other Therapeutic Option Wall Street Transcript
24-Apr-13 09:13AM  Target Executive Officer Sells More Than 41K Shares and 4 Insider Sales to Note at Wall St. Cheat Sheet
21-Apr-13 01:46PM  Did These Stocks Miss or Beat Analyst Expectations? at Wall St. Cheat Sheet
19-Apr-13 02:20PM  Covidien Expands Shiley Offerings Zacks +5.40%
01:40PM  FDA Nod for Luminex Offering Zacks
10:50AM  Cepheid Earnings Beat, Retains Outlook Zacks
08:45AM  Cepheid should be bought into strength, says RW Baird at theflyonthewall.com
18-Apr-13 09:20PM  Cepheid Management Discusses Q1 2013 Results - Earnings Call Transcript at Seeking Alpha
06:34PM  Cepheid posts 1Q profit as sales improve AP
05:19PM  Cepheid Earnings: Heres Why Investors are Excited Now at Wall St. Cheat Sheet
04:08PM  InPlay: Cepheid beats by $0.01, beats on revs; guides FY13 EPS in-line, revs in-line Briefing.com
04:05PM  Cepheid Reports 2013 First Quarter Results PR Newswire
03:10PM  New Patent for Biolase Zacks
02:30PM  Myriad Downgraded to Neutral Zacks
02:20PM  Volcano Corporation Stays Neutral Zacks
01:40PM  Encouraging 4Q Prelims for Abiomed Zacks
09:16AM  CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:07AM  Q1 2013 Cepheid Earnings Release - After Market Close CCBN
17-Apr-13 06:35PM  AK Steel to Lift up Steel Prices Zacks
02:35PM  More Backing for HOLX Tomosynthesis Zacks
02:15PM  Varian Applies Latest Vitesse Zacks
12:20PM  Another Earnings Miss for DGX Zacks
16-Apr-13 05:10PM  Covance Augments Singapore Facility Zacks
15-Apr-13 03:50PM  Biolase Gets FDA Nod for EPIC 10S Zacks
02:20PM  BSX Precision System Now in U.S. Zacks
12-Apr-13 01:50PM  Cyberonics Stands Out at Outperform Zacks
01:40PM  Thoratec Upgraded to Neutral Zacks
08:30AM  FDA Approves TFX's ISO-Gard Mask Zacks
11-Apr-13 02:10PM  Product Recall Plagues Integra Zacks
10-Apr-13 04:31PM  BioScrip Raised to Outperform Zacks
02:20PM  Merge Enhances eClinical OS Platform Zacks
09-Apr-13 01:50PM  Safeway's Blackhawk Settles IPO Price Zacks
12:36PM  [video] Chinas Slowing Inflation Is Good News for Asia at MarketWatch
12:35PM  [video] Chinas Slowing Inflation Is Good News for Asia at MarketWatch
08:10AM  ANGO Posts Dismal 3Q Earnings Zacks
12:02AM  [video] Chinas Slowing Inflation Is Good News for Asia at MarketWatch
08-Apr-13 02:30PM  CYBX Resumes Reimbursement Efforts Zacks
01:50PM  Hologic Reiterated at Neutral Zacks
05-Apr-13 01:48PM  Milestone for Accuray TomoTherapy Zacks
01:38PM  Still Neutral on Merge Healthcare Zacks
04-Apr-13 04:05PM  Cepheid Schedules 2013 First Quarter Results Announcement And Webcast PR Newswire
01:38PM  Mindray to Exhibit at CMEF Zacks
03-Apr-13 08:08AM  Abiomed Begins Impella RP Trial Zacks
02-Apr-13 01:48PM  ResMed Protects Patent Landscape Zacks
28-Mar-13 04:46PM  Cepheid Larger Than S&P 500 Component First Solar at Forbes
06-Mar-13 01:04PM  CEPHEID Financials EDGAR Online Financials
05-Mar-13 11:41AM  Luminex Has Both Many Opportunities And Many Questions To Answer at Seeking Alpha
28-Feb-13 04:10PM  CEPHEID Files SEC form 10-K, Annual Report EDGAR Online
25-Feb-13 11:56AM  9.1% of TB Drugs Fail Quality Control at Motley Fool
21-Feb-13 01:48PM  Collaborative Research for Cepheid Zacks
19-Feb-13 04:57PM  Cepheid plans breast and prostate cancer test AP
04:06PM  InPlay: Cepheid and Oregon Health & Science University collaborate to develop Oncology Assays for GeneXpert System Briefing.com
04:05PM  Cepheid And Oregon Health & Science University Collaborate To Develop Oncology Assays For GeneXpert® System PR Newswire
14-Feb-13 04:22PM  CEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
04:07PM  InPlay: Cepheid announces its Board of Directors has elected John Bishop as Chairman of the Board and named Cristina Kepner as Lead Independent Director, effective February 12, 2013 Briefing.com
04:05PM  Cepheid Announces Board of Directors Changes PR Newswire
12-Feb-13 01:58PM  Still Neutral on Cepheid Zacks
04-Feb-13 04:12PM  CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
01-Feb-13 02:08PM  Abaxis Surpasses Estimates in 3Q Zacks
31-Jan-13 04:05PM  Cepheid to Webcast Upcoming Financial Presentations PR Newswire
28-Jan-13 08:08AM  All-Front Easy Beat for Covance Zacks
27-Jan-13 09:21AM  New Star Analyst Rankings for CEPHEID StarMine
25-Jan-13 10:23AM  Cepheid Under Pressure and 4 Stock Analyses Making Rounds at Wall St. Cheat Sheet +6.62%
10:18AM  Cepheid Turns to Profit in 4Q Zacks
09:19AM  New Star Analyst Rankings for CEPHEID StarMine
04:00AM  Cepheid Stock Upgraded (CPHD) at TheStreet
24-Jan-13 11:30PM  Cepheid's CEO Discusses Q4 2012 Results - Earnings Call Transcript at Seeking Alpha
04:13PM  InPlay: Cepheid beats by $0.09, reports revs in-line; guides FY13 EPS below consensus, revs below consensus Briefing.com
04:11PM  CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:05PM  Cepheid Reports Fourth Quarter And Full Year 2012 Results PR Newswire
22-Jan-13 02:17PM  VeriFone Performance Remains Strong and 4 Must-See Stock Analyses at Wall St. Cheat Sheet
08:54AM  Week Ahead Market Report: 1/22/13 at Forbes
16-Jan-13 04:11PM  CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers, Other Events EDGAR Online
02:18PM  FDA Categorizes Cepheid's New Test Zacks
12:53PM  Wedge Down Equals Thumbs Up at Investopedia
15-Jan-13 07:25AM  InPlay from Briefing.com Briefing.com
07:03AM  InPlay: Cepheid announces Chlamydia and N. gonorrhoeae test categorized 'Moderate Complexity' by FDA Briefing.com
07:00AM  Cepheid Announces Chlamydia and N. gonorrhoeae Test Categorized 'Moderate Complexity' by FDA PR Newswire
10-Jan-13 02:08PM  Cepheid Unveils Prelim 4Q Results Zacks
08-Jan-13 04:55PM  Cepheid shares rise on 4Q guidance AP
02:26PM  Strong Flu Could Boost Some Health Care Profits at CNBC
12:43PM  Why Cepheid Shares Popped at Motley Fool
10:20AM  Cepheid rises after saying Q4 EPS should beat prior guidance at theflyonthewall.com
08:47AM  CEPHEID Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
08:30AM  Cepheid Announces Update On Xpert® Test Availability PR Newswire
04-Jan-13 11:16AM  Cepheid Pullback Viewed as Overdone and 4 Stock Analyses to Know Now at Wall St. Cheat Sheet
03-Jan-13 12:31PM  Ross Among the Nasdaq's Biggest Movers on January 3, 2013 at Investopedia
12:31PM  Technology Stocks, Including Mindray Medical International Ltd, Making Big Moves on January 3, 2013 at Investopedia
02-Jan-13 11:57AM  Medtech News Over The Christmas Period at Seeking Alpha
30-Dec-12 11:13AM  Cepheid Wins FDA Clearance for Xpert CT/NG, TranS1 Settles with DOJ: Healthcare Business Recap at Wall St. Cheat Sheet
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. Cepheid also provides GeneXpert Infinity System for high volume testing. The company offers tests for the GeneXpert and the SmartCycler systems in the areas of healthcare associated infections, critical infectious disease, sexual health, women's health, virology, oncology, and genetics. Cepheid sells its products through its direct sales force and through third-party distributors worldwide. It has collaboration agreements with Novartis for the commercialization of a test for monitoring the BCR-ABL gene transcript in peripheral blood specimens; and Life Technologies Corporation to develop reagents for use in the USPS BDS program. The company was founded in 1996 and is headquartered in Sunnyvale, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FLOM KERRYEVP, Regulatory AffairsMay 13Option Exercise13.256,25082,78826,832May 14 04:15 PM
FLOM KERRYEVP, Regulatory AffairsMay 13Sale39.766,832271,64620,000May 14 04:15 PM
BISHOP JOHN LChairman of the Board and CEOApr 29Option Exercise0.001,250034,066May 01 05:07 PM
Miller AndrewEVP, CFOApr 29Option Exercise0.001,250012,938May 01 05:09 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerApr 29Option Exercise0.0033904,813May 01 05:10 PM
SMITH JOSEPH HEVP, Bus Dev and GCApr 29Option Exercise0.0031308,892May 01 05:12 PM
Reyes HumbertoExecutive VP, COOApr 29Option Exercise0.00339016,885May 01 05:11 PM
STEELE GLENN JR MD PHDDirectorApr 26Option Exercise0.0070004,583Apr 30 04:05 PM
BISHOP JOHN LChairman of the Board and CEOApr 25Option Exercise0.001,563033,632Apr 25 08:32 PM
FLOM KERRYEVP, Regulatory AffairsApr 25Option Exercise0.00237020,659Apr 25 08:34 PM
Miller AndrewEVP, CFOApr 25Option Exercise0.00250011,782Apr 25 08:37 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerApr 25Option Exercise0.0030204,588Apr 25 08:39 PM
Reyes HumbertoExecutive VP, COOApr 25Option Exercise0.00313016,664Apr 25 08:40 PM
SMITH JOSEPH HEVP, Bus Dev and GCApr 25Option Exercise0.0025008,710Apr 25 08:41 PM
EASTON ROBERT JDirectorApr 24Option Exercise0.001,050078,782Apr 25 08:34 PM
FLOM KERRYEVP, Regulatory AffairsApr 24Option Exercise0.00625020,625Apr 25 08:34 PM
Brown Thomas DDirectorApr 24Option Exercise0.001,050026,338Apr 25 08:33 PM
BISHOP JOHN LChairman of the Board and CEOApr 24Option Exercise0.004,250034,287Apr 25 08:32 PM
GUTSHALL THOMAS LDirectorApr 24Option Exercise0.001,050090,175Apr 25 08:35 PM
KEPNER CRISTINADirectorApr 24Option Exercise0.001,0500225,779Apr 25 08:36 PM
Miller AndrewEVP, CFOApr 24Option Exercise0.001,355012,042Apr 25 08:37 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerApr 24Option Exercise0.001,35504,796Apr 25 08:39 PM
MORTON DEAN ODirectorApr 24Option Exercise0.001,050015,650Apr 25 08:38 PM
RENTON HOLLINGSDirectorApr 24Option Exercise0.001,05008,650Apr 25 08:39 PM
Reyes HumbertoExecutive VP, COOApr 24Option Exercise0.001,355016,861Apr 25 08:40 PM
SMITH JOSEPH HEVP, Bus Dev and GCApr 24Option Exercise0.0062508,787Apr 25 08:41 PM
STEELE GLENN JR MD PHDDirectorApr 24Option Exercise0.001,05003,883Apr 25 08:42 PM
GUTSHALL THOMAS LDirectorApr 24Sale38.003,000113,999397,800Apr 25 08:35 PM
BISHOP JOHN LChairman of the Board and CEOApr 22Option Exercise9.18134,7991,237,455164,836Apr 23 04:06 PM
BISHOP JOHN LChairman of the Board and CEOApr 22Sale37.51134,7995,056,02730,037Apr 23 04:06 PM
Miller AndrewEVP, CFOApr 03Option Exercise0.00625010,922Apr 04 08:32 PM
GUTSHALL THOMAS LDirectorFeb 25Sale36.423,000109,273682,300Feb 25 04:13 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerFeb 22Option Exercise7.3815,000110,70018,441Feb 25 04:13 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerFeb 22Sale36.1315,000541,9943,441Feb 25 04:13 PM
SMITH JOSEPH HEVP, Bus Dev and GCFeb 21Option Exercise4.3010438,172Feb 25 04:12 PM
SMITH JOSEPH HEVP, Bus Dev and GCFeb 21Sale35.53103558,162Feb 25 04:12 PM
Brown Thomas DDirectorFeb 08Option Exercise9.1810,00091,80030,358Feb 12 04:05 PM
EASTON ROBERT JDirectorFeb 08Option Exercise9.1812,500114,75089,842Feb 12 04:06 PM
EASTON ROBERT JDirectorFeb 08Sale36.0512,500450,67577,342Feb 12 04:06 PM
Brown Thomas DDirectorFeb 08Sale36.073,054110,15624,758Feb 12 04:05 PM
SMITH JOSEPH HEVP, Bus Dev and GCFeb 04Option Exercise9.1138,400349,82446,562Feb 06 04:14 PM
SMITH JOSEPH HEVP, Bus Dev and GCFeb 04Sale36.2038,4001,390,2228,162Feb 06 04:14 PM
SMITH JOSEPH HEVP, Bus Dev and GCJan 29Option Exercise0.0031207,613Jan 30 04:14 PM
Reyes HumbertoExecutive VP, COOJan 29Option Exercise0.00338014,926Jan 30 04:13 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerJan 29Option Exercise0.0033803,508Jan 30 04:12 PM
Miller AndrewEVP, CFOJan 29Option Exercise0.001,250010,756Jan 30 04:11 PM
BISHOP JOHN LCEOJan 29Option Exercise0.001,250030,409Jan 30 04:11 PM
FLOM KERRYEVP, Regulatory AffairsJan 28Sale37.311475,48520,000Jan 30 04:10 PM
FLOM KERRYEVP, Regulatory AffairsJan 25Option Exercise30.336,487196,78126,250Jan 28 04:09 PM
Reyes HumbertoExecutive VP, COOJan 25Option Exercise0.00312014,725Jan 28 04:11 PM
SMITH JOSEPH HEVP, Bus Dev and GCJan 25Option Exercise0.0025007,411Jan 28 04:12 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerJan 25Option Exercise0.0030203,303Jan 28 04:11 PM
Miller AndrewEVP, CFOJan 25Option Exercise0.0025009,598Jan 28 04:10 PM
BISHOP JOHN LCEOJan 25Option Exercise0.001,562029,844Jan 28 04:08 PM
FLOM KERRYEVP, Regulatory AffairsJan 25Sale38.006,250237,50020,000Jan 28 04:09 PM
GUTSHALL THOMAS LDirectorJan 24Sale35.203,000105,599685,300Jan 28 04:08 PM
Miller AndrewEVP, CFOJan 03Option Exercise0.002,500010,520Jan 07 04:08 PM
Enns RussellSr. VP, RegulatoryDec 31Option Exercise0.004,12506,528Jan 03 04:11 PM
GUTSHALL THOMAS LDirectorDec 24Sale33.063,00099,193688,300Dec 27 04:07 PM
KEPNER CRISTINADirectorDec 18Option Exercise10.1620,000203,250224,156Dec 19 04:06 PM
KEPNER CRISTINADirectorDec 17Option Exercise7.6920,000153,750204,156Dec 19 04:06 PM
GUTSHALL THOMAS LDirectorNov 27Option Exercise10.8320,222219,013109,347Nov 29 04:26 PM
GUTSHALL THOMAS LDirectorNov 27Sale31.8020,222643,14989,125Nov 29 04:26 PM
GUTSHALL THOMAS LDirectorNov 26Option Exercise9.184,77843,86293,903Nov 27 04:10 PM
GUTSHALL THOMAS LDirectorNov 26Sale31.833,00095,494691,300Nov 27 04:10 PM
GUTSHALL THOMAS LDirectorNov 26Sale32.004,778152,89889,125Nov 27 04:10 PM
SMITH JOSEPH HSVP, Bus Dev and GCOct 29Option Exercise0.0031307,308Oct 31 04:32 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerOct 29Option Exercise0.0033903,160Oct 31 04:31 PM
Reyes HumbertoExecutive VP, COOOct 29Option Exercise0.00339014,572Oct 31 04:31 PM
Miller AndrewEVP, CFOOct 29Option Exercise0.001,25008,604Oct 31 04:30 PM
BISHOP JOHN LCEOOct 29Option Exercise0.001,250028,866Oct 31 04:28 PM
Enns RussellSr. VP, RegulatoryOct 29Option Exercise0.0027102,530Oct 31 04:29 PM
ARNOLD NICOLAASEVP, Worldwide Comm'l OpsOct 29Option Exercise0.0034403,589Oct 31 04:27 PM
Miller AndrewEVP, CFOOct 25Option Exercise0.0025007,471Oct 31 04:30 PM
SMITH JOSEPH HSVP, Bus Dev and GCOct 25Option Exercise0.0025007,112Oct 29 04:08 PM
SMITH JOSEPH HSVP, Bus Dev and GCOct 25Option Exercise0.0025007,112Oct 29 04:09 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerOct 25Option Exercise0.0030202,962Oct 29 04:07 PM
Reyes HumbertoExecutive VP, COOOct 25Option Exercise0.00313014,380Oct 29 04:08 PM
Enns RussellSr. VP, RegulatoryOct 25Option Exercise0.0025002,376Oct 29 04:06 PM
Enns RussellSr. VP, RegulatoryOct 25Option Exercise0.0025002,376Oct 29 04:07 PM
ARNOLD NICOLAASEVP, Worldwide Comm'l OpsOct 25Option Exercise0.0025003,362Oct 29 04:05 PM
BISHOP JOHN LCEOOct 25Option Exercise0.001,563028,346Oct 29 04:06 PM
GUTSHALL THOMAS LDirectorOct 24Sale31.503,00094,502694,300Oct 25 04:05 PM
EASTON ROBERT JDirectorOct 22Option Exercise7.357,50055,12584,360Oct 23 04:06 PM
EASTON ROBERT JDirectorOct 22Sale31.637,500237,19276,860Oct 23 04:06 PM
GUTSHALL THOMAS LDirectorSep 24Sale40.133,000120,404697,300Sep 25 04:05 PM
ARNOLD NICOLAASEVP, Worldwide Comm'l OpsAug 30Option Exercise14.9315,000223,95018,112Aug 30 08:31 PM
EASTON ROBERT JDirectorAug 30Option Exercise5.207,50039,00084,360Aug 30 08:32 PM
ARNOLD NICOLAASEVP, Worldwide Comm'l OpsAug 30Sale37.1215,000556,7843,112Aug 30 08:31 PM
GUTSHALL THOMAS LDirectorAug 30Sale37.4140,0001,496,564700,300Aug 30 08:32 PM
EASTON ROBERT JDirectorAug 30Sale36.827,500276,15076,860Aug 30 08:32 PM
GUTSHALL THOMAS LDirectorAug 24Sale35.973,000107,910740,300Aug 27 04:05 PM
SMITH JOSEPH HSVP, Bus Dev and GCJul 29Option Exercise0.0031206,917Jul 31 04:09 PM
Miller AndrewEVP, CFOJul 29Option Exercise0.001,25007,805Jul 31 04:07 PM
PERSING DAVID HExec VP,Chief Med/Tech OfficerJul 29Option Exercise0.0033802,736Jul 31 04:08 PM
Reyes HumbertoExecutive VP, COOJul 29Option Exercise0.00338014,191Jul 31 04:08 PM
Enns RussellSr. VP, RegulatoryJul 29Option Exercise0.0027002,253Jul 31 04:07 PM
BISHOP JOHN LCEOJul 29Option Exercise0.001,250027,262Jul 31 04:06 PM
ARNOLD NICOLAASEVP, Worldwide Comm'l OpsJul 29Option Exercise0.0034302,695Jul 31 04:06 PM
SMITH JOSEPH HSVP, Bus Dev and GCJul 25Option Exercise0.0025006,722Jul 26 04:10 PM
open in yahoo | open in reuters | open in google